{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:16:30Z","timestamp":1784798190466,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.vaccine.2022.06.058","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T02:50:45Z","timestamp":1656039045000},"page":"5539-5541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Considerations for the chemistry, manufacturing and Controls (CMC) - quality package for COVID-19 vaccines- interim lessons learnt by the European medicines Agency (EMA)"],"prefix":"10.1016","volume":"40","author":[{"given":"Ragini","family":"Shivji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Conocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evdokia","family":"Korakianiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Jekerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.06.058_b0005","unstructured":"As of April 2022, aside from the five vaccines already approved (Comirnaty, Spikevax, Vaxzevria, COVID-19 vaccine Janssen and Nuvaxovid) four applications are under review via rolling review mechanism for MA and many more vaccines are in clinical development. The European Public Assessment reports for the authorised products can be accessed here. COVID-19 vaccines | European Medicines Agency (europa.eu) https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/covid-19-vaccines Accessed 01\/04\/2022."},{"key":"10.1016\/j.vaccine.2022.06.058_b0010","unstructured":"COVID-19 guidance: research and development | European Medicines Agency (europa.eu). https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/guidance-developers-companies\/covid-19-guidance-research-development#rapid-procedures-section. Accessed 25\/01\/2022."},{"key":"10.1016\/j.vaccine.2022.06.058_b0015","unstructured":"Toolbox guidance on scientific elements and regulatory tools to support quality data packages for PRIME marketing authorisation applications | European Medicines Agency (europa.eu). https:\/\/www.ema.europa.eu\/en\/toolbox-guidance-scientific-elements-regulatory-tools-support-quality-data-packages-prime-marketing. Accessed 25\/01\/2022."},{"key":"10.1016\/j.vaccine.2022.06.058_b0020","unstructured":"Good manufacturing practice | European Medicines Agency (europa.eu). https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compliance\/good-manufacturing-practice. Accessed 25\/01\/2022."},{"key":"10.1016\/j.vaccine.2022.06.058_b0025","unstructured":"EDQM Questions and answers on OCABR | EDQM - European Directorate for the Quality of Medicines. https:\/\/www.edqm.eu\/en\/omcls-questions-and-answers-ocabr Accessed 25\/01\/2022."},{"key":"10.1016\/j.vaccine.2022.06.058_b0030","unstructured":"Regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2 | European Medicines Agency (europa.eu). https:\/\/www.ema.europa.eu\/en\/regulatory-requirements-vaccines-intended-provide-protection-against-variant-strains-sars-cov-2. Accessed 25\/01\/2022."},{"key":"10.1016\/j.vaccine.2022.06.058_b0035","unstructured":"ICMRA Statement on Pre-Requisites for Regulatory Flexibility in Pharmaceutical Manufacturing Change Management | International Coalition of Medicines Regulatory Authorities (ICMRA). https:\/\/www.icmra.info\/drupal\/en\/covid-19\/icmra_statement_on_flexibility_in_manufacturing_change_management. Accessed 25\/01\/2022."},{"key":"10.1016\/j.vaccine.2022.06.058_b0040","unstructured":"Accumulus Synergy | Biopharma Information Exchange Platform https:\/\/www.accumulus.org\/ Accessed 22\/02\/2022."},{"key":"10.1016\/j.vaccine.2022.06.058_b0045","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.vaccine.2021.11.098","article-title":"How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation","volume":"40","author":"Mic McGoldrick","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.058_b0050","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.vaccine.2021.12.038","article-title":"How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation","volume":"40","author":"Mic McGoldrick","year":"2022","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22008271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22008271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:14:55Z","timestamp":1759403695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22008271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":10,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0264410X22008271"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.058","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations for the chemistry, manufacturing and Controls (CMC) - quality package for COVID-19 vaccines- interim lessons learnt by the European medicines Agency (EMA)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}